Is There a Difference between the Allergic Potencies of the Iron Sucrose and Low Molecular Weight Iron Dextran?
- 1 January 2007
- journal article
- research article
- Published by Taylor & Francis Ltd in Renal Failure
- Vol. 29 (4), 423-426
- https://doi.org/10.1080/08860220701278208
Abstract
The objectives of the present trial were to compare the side effects and safety of two intravenous iron preparations (iron-dextran, iron-sucrose) in patients with end stage renal disease. A total of 60 patients were randomized and assigned to one of two treatment groups (iron-dextran, n = 30; iron-sucrose, n = 30). A standard test dose of 25 mg of low molecular weight iron-dextran and iron-sucrose were administered over 15 minutes during the initial visit, monitoring very closely for adverse reactions. If this dose was well tolerated, 75 mg of iron diluted in 100 mL of normal saline was administered over 30 minutes. Adverse reactions were recorded. The mean age of the patients was 51.5+/-17.4 years (range, 21 to 80 years). Of the 30 patients who received low molecular weight iron-dextran, 11 developed side effects (pruritus, 1 patient; wheezing, 1 patient; chest pain, 1 patient; nausea, 4 patients; hypotension, 1 patient; swelling, 1 patient; headache, 2 patients). Of the 30 patients who received iron-sucrose, 13 developed side effects (pruritus, 1 patient; wheezing, 1 patient; diarrhea, 1 patient; nausea, 4 patients; hypotension, 2 patients; swelling, 1 patient; headache, 3 patients). Adverse events occurred with similar frequency in the two treatment groups in our study (p > 0.05). We did not observe any serious reactions in the two groups. We conclude that the incidence of side effects associated with iron-dextran was not different than that of iron-sucrose in our study. Large scale randomized studies are needed to compare the full side effect profile of intravenous iron preparations more precisely.Keywords
This publication has 14 references indexed in Scilit:
- Administration of Intravenous Iron Sucrose as a 2-Minute Push to CKD Patients: A Prospective Evaluation of 2,297 InjectionsAmerican Journal of Kidney Diseases, 2005
- Hypersensitivity reactions and deaths associated with intravenous iron preparationsNephrology Dialysis Transplantation, 2005
- Benchmarking iron dextran sensitivity: reactions requiring resuscitative medication in incident and prevalent patientsNephrology Dialysis Transplantation, 2005
- Intravenous iron sucrose: Establishing a safe doseAmerican Journal of Kidney Diseases, 2001
- Intravenous iron dextran treatment in predialysis patients with chronic renal failureAmerican Journal of Kidney Diseases, 2000
- Safety and efficacy of iron sucrose in patients sensitive to iron dextran: North American clinical trialAmerican Journal of Kidney Diseases, 2000
- Iron Metabolism in End‐Stage Renal DiseaseSeminars in Dialysis, 1999
- Toxicity of parenteral iron dextran therapyKidney International, 1999
- Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysisAmerican Journal of Kidney Diseases, 1996
- Efficacy of oral iron therapy in patients receiving recombinant human erythropoietinAmerican Journal of Kidney Diseases, 1995